BCM
ANTX icon

BML Capital Management’s AN2 Therapeutics ANTX Stock Holding History

BML Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,749,432
Closed -$7.82M – 25
2025
Q1 		$7.82M Hold
5,749,432
– – 6.33% 5
2024
Q4 		$7.93M Hold
5,749,432
– – 4.93% 5
2024
Q3 		$6.15M Buy
+5,749,432
New +$9.98M 3.62% 8

Other funds holding ANTX

AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BML Capital Management's ANTX Position: Q2 2025 in Review

BML Capital Management sold out of AN2 Therapeutics (ANTX) in Q2 2025, closing a stake of 5,749,432 shares — an estimated $7.82M sold.

BML Capital Management first reported a position in ANTX in Q3 2024 and held it in 3 quarters. The position peaked at $7.93M in Q4 2024. 36 funds tracked by Wall St. Rank hold ANTX as of Q2 2025.

  • BML Capital Management reported no remaining AN2 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • BML Capital Management sold 5,749,432 AN2 Therapeutics shares in Q2 2025, an estimated $7.82M.
  • BML Capital Management first reported a position in AN2 Therapeutics in Q3 2024 and held it in 3 quarters.
  • BML Capital Management's AN2 Therapeutics position peaked at $7.93M in Q4 2024.
  • 36 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2025.

Based on BML Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.